- Corporate Strategy
- Portfolio Planning
- Business Development Support
We evaluated the strategic options for a European biotechnology company to allow the company to transition from a distributor model to a company operations model across Eastern Europe, Middle East and North Africa.
Undertook a full assessment of how a leading European biotechnology company could build a more significant proprietary therapeutic antibody pipeline within a time span of three to five years.
Advised a UK Private hospital group on the strategic options for rationalising the number of hospitals in one region while continuing to provide the full range of clinical services.